AMC Entertainment Holdings, Inc.
AMC is still a weak business with too much debt, but at 0.32x sales and with a credible path to better cash generation after a record Q2, the equity still has upside to $4.23 if 2026 box office strength carries through and refinancing keeps pushing maturities out.
AMC is a balance-sheet trade wrapped inside a cyclical recovery. The core mispricing is not that this is a great business. It is that the market is still valuing AMC as if every improvement in attendance and margin will be swallowed by debt and dilution, even after a quarter that showed the opposite. Q2 2026 revenue reached $1.60B, adjusted EBITDA hit a company record $321.4M, and free cash flow was $190.1M. Those numbers matter because they show the asset base can still convert a decent slate into real cash when utilization improves.
The first thing the case depends on is box office staying healthy enough to keep AMC above its cash break line. Management put domestic free-cash-flow breakeven at about $10.4B on a 12-month basis. That is not a wide margin of safety, but it is lower than many investors likely assume given seven years of inflation since 2019. If 2026 does become, in management's words, the strongest post-pandemic year, then AMC's earnings power is far better than FY2025 EPS of -$1.23 suggests. The right lens here is normalized EBITDA and cash generation, not trailing GAAP earnings.
The second thing the case depends on is debt not forcing value destruction before operations normalize. Here, the evidence is improving. AMC refinanced $400M of debt, redeemed $125.5M of notes, expects about $16M of annual cash interest savings from Q2 actions, another $51M from leverage-triggered rate step-downs, and says no material principal repayments are due before 2029. That buys time, which is exactly what a levered cyclical recovery needs.
The third thing the case depends on is dilution not overwhelming operating progress. This is the hardest part of the story and why conviction stays low. $7.7B of debt, a 0.55 current ratio, and a share count that has already ballooned mean common equity holders still own the residual claim in a heavily encumbered business. But at $2.65, the market cap is only $2.4B, the stock is still 16.7% below the 52-week high despite being up sharply from the lows, and the valuation remains depressed at 0.32x sales. That leaves room for upside if AMC can deliver even two more quarters that look meaningfully closer to Q2 2026 than to FY2025.
AMC compounds multiple quarters of Q2-like cash generation, executes PLF/XLF expansion with limited capital, and the market begins to price equity on normalized EBITDA rather than survival.
2026 box office strength holds, refinancing savings flow through, and the stock closes part of the gap from 0.32x sales toward a more reasonable distressed-recovery multiple.
Box office slips back below AMC's $10.4B breakeven level, dilution resumes, and the market re-rates the equity as an option on a $7.7B debt stack.
Quant call aligns with analyst consensus (Buy: 2 buy / 2 hold / 1 sell).
Never, ever invest in the present.
Forward earnings power is the whole case because trailing earnings are still negative. If 2026 truly becomes the strongest post-pandemic box office year and AMC keeps even part of the Q2 2026 19.7%-20.1% adjusted EBITDA margin, the market will start valuing normalized EBITDA and sales rather than FY2025 EPS of -$1.23, which makes the trailing P/E irrelevant and leaves 0.32x sales looking too low. The moat is narrower than it was 10 years ago because theaters do not control content and streaming keeps shrinking exclusivity windows, but premium formats, recliner-upgraded sites, food and beverage mix, and scale in the U.S. and Europe still support a viable cash business over the next 3-5 years. AI is more likely a mild disruption than an advantage: it can lower content production costs and expand film supply over time, but it also improves at-home entertainment discovery and personalization, which pressures theatrical frequency. Regulation is not the key swing factor here, leverage and content cadence are.
- Q2 2026 adjusted EBITDA of $321.4M on $1.60B revenue, up 70% y/y, showed real operating leverage and cost control.
- No material principal debt payments before 2029, plus ~$16M annual cash interest savings from Q2 refinancing actions and ~$51M from leverage-triggered rate step-downs, improve survival odds.
- The stock trades at 0.32x sales versus peers at 1.0x, and the quant engine's $4.23 target implies 59.6% upside from $2.65.
- FY2025 revenue was $4.8B despite a weak release environment, and management now says 2026 should be the strongest post-pandemic box office year, which matters because the business already produced $190.1M of Q2 free cash flow when content normalized.
- AMC generated 20.1% / 19.7% Q2 adjusted EBITDA margin versus 14.6% a year earlier, a 510 bps y/y improvement, with roughly 66% flow-through on about $200M of incremental revenue.
- Balance sheet pressure eased at the margin: AMC refinanced $400M of 2027 debt out four years, redeemed $125.5M of 6.125% notes, and now expects no material principal repayments before 2029.
- Operating assets are still being upgraded with limited balance-sheet strain: management targets 100-250 more PLF/XLF auditoriums over 2-4 years, largely with third-party capital, while continuing to close underperforming locations.
- The capital structure still dominates the story: $7.7B of debt, 35.77x debt/EBITDA, and a 0.55 current ratio leave little room for a box-office stumble.
- AMC remains structurally unprofitable on a full-year basis, with FY2025 EPS of -$1.23, operating margin of -1.7%, and net margin of -7.6%.
- Management explicitly said AMC is not yet free-cash-flow positive on a full 12-month basis, and domestic box office must be around $10.4B just to reach free-cash-flow breakeven.
- Equity dilution remains a live risk. Recent debt paydown included a $125.5M note redemption after a recent equity raise, and the float is already 832M shares, with recent press focused on 892 million shares of dilution context.
| Metric | Value | Context |
|---|---|---|
| Current price | $2.65 | Basis for engine upside calculation |
| Quant price target | $4.23 | 59.6% upside, Medium confidence, basis sales_quality_blend |
| FY2025 revenue | $4.8B | -3.6% YoY, still below a stable recovery path |
| FY2025 EPS | -$1.23 | -15.9% YoY, trailing P/E not meaningful |
| FY2025 operating margin | -1.7% | Flat versus prior FY, showing limited full-year margin repair |
| FY2025 net margin | -7.6% | Profitability remains negative despite recovery efforts |
| Valuation | 0.32x P/S | Versus peer average 1.0x, reflecting distress and dilution risk |
| Debt load | $7.7B total debt | 35.77x debt/EBITDA, the main equity overhang |
| Liquidity | 0.55 current ratio | Thin near-term cushion despite refinancing progress |
| Cash generation | $0.2B FCF | Positive in FY2025, with Q2 2026 FCF at $190.1M |
| Q2 2026 adjusted EBITDA | $321.4M | Record quarter, +70% y/y on $1.60B revenue |
| 52-week position | $0.93-$3.18 range | Current price is -16.7% vs high and 47.7% above 200-day average |
The biggest risk is that box office undershoots AMC's ~$10.4B domestic free-cash-flow breakeven level, leaving a company with $7.7B of debt and a 0.55 current ratio dependent on more equity issuance.
The next catalyst is Q3 earnings on November 4, 2026, which will show whether the record Q2 2026 cash generation was the start of a sustained recovery or just a slate-driven spike.
Positioning is not stretched enough to be the thesis by itself. Short interest is 42.4M shares, or 5.10% of float, down 8.8%, with only 1.1 days-to-cover, which means squeeze mechanics are possible but not a strong standalone driver. Institutional ownership is still light at the top, with the top three holders at only 14.4%, insider ownership is just 0.3%, and the stock sits 47.7% above its 200-day average, so momentum has improved but speculative ownership still matters.
The call points to major contribution from admissions and high-margin food and beverage, but no FY2025 segment split was provided.
Management said both domestic and Europe outperformed industry growth on admissions and attendance in Q2 2026.
AMC added 6 PLF and 25 XL auditoriums in Q2 and targets 100-250 more over 2-4 years, signaling that premium screens are a strategic growth pocket.
AMC posted a record Q2 and sees 2026 as the strongest post-pandemic year for box office.
Execution has improved, but credibility is mixed rather than clean. On the positive side, the 2024 Q3 call promised stronger cash flow and continued balance-sheet repair, and since then AMC has extended maturities again, including $400M of 2027 debt pushed out by four years, redeemed $125.5M of notes, and now says there are no material principal payments before 2029. The 2024 Q3 call also laid out 50-100 XL screens in 2025 and a broader G.O. Plan, and by Q2 2026 AMC was still investing in that direction, adding 6 PLF and 25 XL auditoriums in the quarter and targeting 100-250 more PLF/XLF sites over 2-4 years. On operations, management said in 2024 that Q4 operating cash flow would be positive and that 2025 domestic box office should beat 2024. The company did produce cash, but full-year outcomes remained weak, with FY2025 revenue down 3.6%, operating margin at -1.7%, and EPS at -$1.23. Recent quarter execution is stronger, with three straight beats in 2026 including 0.14 vs 0.03 in July, but the large November 2025 miss of -205.9% is a reminder that results remain slate-sensitive and management should not be given full credit until the 12-month free-cash-flow profile turns sustainably positive.
AMC reported record adjusted EBITDA of $321.4 million in Q2 of 2026.
Accordingly, we believe that movie theaters will enjoy in the full 12 months of 2026, their strongest yet post-pandemic year at both the domestic box office and at the global box office.
And we expect net CapEx for 2026 to be between $200 million and $235 million.
As a result of the debt refinancing and repayment actions taken in the second quarter, we do not anticipate any material debt principal payments required prior to 2029, and our go-forward annual cash interest expense will be reduced by approximately $16 million.
Right now, it's right around $10.4 billion, which is so impressive because we've -- if you compare what it was back in 2019, pre-pandemic, add 7 years of inflationary costs and wage pressure, among other things, and everything is more expensive that we buy, as everything that everyone buys is more expensive over 7 years.
AMC's moat is not content ownership, it is physical scale, premium screen density, and consumer habit in major markets. The company can spread fixed costs across a very large circuit and use PLF, XL, recliner upgrades, and concession mix to lift per-patron economics when the film slate is healthy. Durability is moderate at best because streaming and shorter windows cap pricing power, but the best-located theaters still retain value that smaller operators struggle to match.
Capital allocation is defensive, not shareholder-friendly. FCF was $0.2B in FY2025 and $190.1M in Q2 2026, but that cash is going toward debt repair, not buybacks or dividends, with both at $0.0B. Net CapEx guidance of $200M-$235M for FY2026 looks disciplined given the balance sheet, and the plan to add 100-250 PLF/XLF auditoriums largely with third-party capital is a sensible way to upgrade the circuit without stretching liquidity further.
AMC rates a BUY at Low conviction. The stock is not a quality story, it is a recovery and balance-sheet extension story, and that distinction matters. The numbers support upside from $2.65 if 2026 box office strength continues and Q2's cash conversion proves repeatable, but the leverage is too high for complacency. A sustained move toward full-year free-cash-flow positivity would raise conviction. A slip back below the $10.4B domestic box-office breakeven path, or renewed heavy dilution, would break the case quickly.
≣ Full research note tap to expand
Executive Summary
BUY, Low conviction. Rated BUY, Low conviction. The stock is not cheap because the business is good, it is cheap because the balance sheet is strained, but the recent operating turn matters: Q2 2026 revenue was $1.60B, adjusted EBITDA was $321.4M, and free cash flow was $190.1M, while debt actions pushed material principal repayments out to 2029. At $2.65, or 16.7% below the 52-week high and only 0.32x FY2025 sales, the market is still pricing AMC as if the Q2 strength is fleeting and dilution will remain endless.
Investment Thesis
AMC is a balance-sheet trade wrapped inside a cyclical recovery. The core mispricing is not that this is a great business. It is that the market is still valuing AMC as if every improvement in attendance and margin will be swallowed by debt and dilution, even after a quarter that showed the opposite. Q2 2026 revenue reached $1.60B, adjusted EBITDA hit a company record $321.4M, and free cash flow was $190.1M. Those numbers matter because they show the asset base can still convert a decent slate into real cash when utilization improves.
The first thing the case depends on is box office staying healthy enough to keep AMC above its cash break line. Management put domestic free-cash-flow breakeven at about $10.4B on a 12-month basis. That is not a wide margin of safety, but it is lower than many investors likely assume given seven years of inflation since 2019. If 2026 does become, in management's words, the strongest post-pandemic year, then AMC's earnings power is far better than FY2025 EPS of -$1.23 suggests. The right lens here is normalized EBITDA and cash generation, not trailing GAAP earnings.
The second thing the case depends on is debt not forcing value destruction before operations normalize. Here, the evidence is improving. AMC refinanced $400M of debt, redeemed $125.5M of notes, expects about $16M of annual cash interest savings from Q2 actions, another $51M from leverage-triggered rate step-downs, and says no material principal repayments are due before 2029. That buys time, which is exactly what a levered cyclical recovery needs.
The third thing the case depends on is dilution not overwhelming operating progress. This is the hardest part of the story and why conviction stays low. $7.7B of debt, a 0.55 current ratio, and a share count that has already ballooned mean common equity holders still own the residual claim in a heavily encumbered business. But at $2.65, the market cap is only $2.4B, the stock is still 16.7% below the 52-week high despite being up sharply from the lows, and the valuation remains depressed at 0.32x sales. That leaves room for upside if AMC can deliver even two more quarters that look meaningfully closer to Q2 2026 than to FY2025.
Key Metrics
| Metric | Value | Context |
|---|---|---|
| Current price | $2.65 | Basis for engine upside calculation |
| Quant price target | $4.23 | 59.6% upside, Medium confidence, basis sales_quality_blend |
| FY2025 revenue | $4.8B | -3.6% YoY, still below a stable recovery path |
| FY2025 EPS | -$1.23 | -15.9% YoY, trailing P/E not meaningful |
| FY2025 operating margin | -1.7% | Flat versus prior FY, showing limited full-year margin repair |
| FY2025 net margin | -7.6% | Profitability remains negative despite recovery efforts |
| Valuation | 0.32x P/S | Versus peer average 1.0x, reflecting distress and dilution risk |
| Debt load | $7.7B total debt | 35.77x debt/EBITDA, the main equity overhang |
| Liquidity | 0.55 current ratio | Thin near-term cushion despite refinancing progress |
| Cash generation | $0.2B FCF | Positive in FY2025, with Q2 2026 FCF at $190.1M |
| Q2 2026 adjusted EBITDA | $321.4M | Record quarter, +70% y/y on $1.60B revenue |
| 52-week position | $0.93-$3.18 range | Current price is -16.7% vs high and 47.7% above 200-day average |
Financial Strength
Financial strength is still weak. AMC has shown that the theater base can throw off meaningful cash in a good quarter, but the balance sheet remains the gating item because $7.7B of debt and a 0.55 current ratio leave the equity very exposed to any setback in content cadence or consumer demand. The important improvement is time: with no material principal payments before 2029 and lower annual cash interest expense ahead, AMC has reduced near-term refinancing stress. Margin trajectory is improving in the right environment, but until positive free cash flow is sustained over a full 12 months, this remains a recovery situation rather than a healthy compounder.
Competitive Position
AMC's moat is not content ownership, it is physical scale, premium screen density, and consumer habit in major markets. The company can spread fixed costs across a very large circuit and use PLF, XL, recliner upgrades, and concession mix to lift per-patron economics when the film slate is healthy. Durability is moderate at best because streaming and shorter windows cap pricing power, but the best-located theaters still retain value that smaller operators struggle to match.
Management & Guidance
Management's current guidance is notably more tangible than prior broad recovery commentary. FY2026 net CapEx is guided to $200M-$235M, annual cash interest expense should fall by about $16M from Q2 refinancing actions, and leverage-linked rate step-downs add another ~$51M of annual interest reduction. The most important operating guidepost is the $10.4B domestic box-office free-cash-flow breakeven level, because it gives investors a measurable hurdle for sustainability. Credibility has improved after three straight 2026 EPS beats and a record Q2, but it is not spotless given the -205.9% miss in November 2025 and the fact that full-year profitability is still negative.
Segment Analysis
- Product/segment revenue (Not disclosed in provided data): The call points to major contribution from admissions and high-margin food and beverage, but no FY2025 segment split was provided.
- United States and Europe exhibition (Not disclosed in provided data): Management said both domestic and Europe outperformed industry growth on admissions and attendance in Q2 2026.
- Premium formats and XLF (Not separately disclosed): AMC added 6 PLF and 25 XL auditoriums in Q2 and targets 100-250 more over 2-4 years, signaling that premium screens are a strategic growth pocket.
Capital Allocation
Capital allocation is defensive, not shareholder-friendly. FCF was $0.2B in FY2025 and $190.1M in Q2 2026, but that cash is going toward debt repair, not buybacks or dividends, with both at $0.0B. Net CapEx guidance of $200M-$235M for FY2026 looks disciplined given the balance sheet, and the plan to add 100-250 PLF/XLF auditoriums largely with third-party capital is a sensible way to upgrade the circuit without stretching liquidity further.
Management Execution & Track Record
Execution has improved, but credibility is mixed rather than clean. On the positive side, the 2024 Q3 call promised stronger cash flow and continued balance-sheet repair, and since then AMC has extended maturities again, including $400M of 2027 debt pushed out by four years, redeemed $125.5M of notes, and now says there are no material principal payments before 2029. The 2024 Q3 call also laid out 50-100 XL screens in 2025 and a broader G.O. Plan, and by Q2 2026 AMC was still investing in that direction, adding 6 PLF and 25 XL auditoriums in the quarter and targeting 100-250 more PLF/XLF sites over 2-4 years. On operations, management said in 2024 that Q4 operating cash flow would be positive and that 2025 domestic box office should beat 2024. The company did produce cash, but full-year outcomes remained weak, with FY2025 revenue down 3.6%, operating margin at -1.7%, and EPS at -$1.23. Recent quarter execution is stronger, with three straight beats in 2026 including 0.14 vs 0.03 in July, but the large November 2025 miss of -205.9% is a reminder that results remain slate-sensitive and management should not be given full credit until the 12-month free-cash-flow profile turns sustainably positive.
Positioning & Flows
Positioning is not stretched enough to be the thesis by itself. Short interest is 42.4M shares, or 5.10% of float, down 8.8%, with only 1.1 days-to-cover, which means squeeze mechanics are possible but not a strong standalone driver. Institutional ownership is still light at the top, with the top three holders at only 14.4%, insider ownership is just 0.3%, and the stock sits 47.7% above its 200-day average, so momentum has improved but speculative ownership still matters.
Bull Case
- FY2025 revenue was $4.8B despite a weak release environment, and management now says 2026 should be the strongest post-pandemic box office year, which matters because the business already produced $190.1M of Q2 free cash flow when content normalized.
- AMC generated 20.1% / 19.7% Q2 adjusted EBITDA margin versus 14.6% a year earlier, a 510 bps y/y improvement, with roughly 66% flow-through on about $200M of incremental revenue.
- Balance sheet pressure eased at the margin: AMC refinanced $400M of 2027 debt out four years, redeemed $125.5M of 6.125% notes, and now expects no material principal repayments before 2029.
- Operating assets are still being upgraded with limited balance-sheet strain: management targets 100-250 more PLF/XLF auditoriums over 2-4 years, largely with third-party capital, while continuing to close underperforming locations.
Bear Case
- The capital structure still dominates the story: $7.7B of debt, 35.77x debt/EBITDA, and a 0.55 current ratio leave little room for a box-office stumble.
- AMC remains structurally unprofitable on a full-year basis, with FY2025 EPS of -$1.23, operating margin of -1.7%, and net margin of -7.6%.
- Management explicitly said AMC is not yet free-cash-flow positive on a full 12-month basis, and domestic box office must be around $10.4B just to reach free-cash-flow breakeven.
- Equity dilution remains a live risk. Recent debt paydown included a $125.5M note redemption after a recent equity raise, and the float is already 832M shares, with recent press focused on 892 million shares of dilution context.
Valuation & Price Target
Engine price target $4.23 (+59.6% vs current), Medium confidence.
- P/S Multiple: $4.78 (45% weight)
- Quality-adjusted: $2.27 (20% weight)
- DCF: $31.33 (1% weight)
The rating stays aligned with the quant baseline BUY, but only at Low conviction because the quality and balance-sheet profile are poor. The engine's $4.23 target is reasonable given 0.32x sales, the sharp improvement in Q2 2026 adjusted EBITDA to $321.4M, and the refinancing path that removes material principal maturities until 2029. The reason conviction is not higher is that the quality score is only 32/100, financial health is 24, debt/EBITDA is 35.77, and the comps framework itself is noisy with 6 peers and 6.7x wide P/E dispersion. Sell-side consensus is also Buy, but that is low-signal context and not the reason for the call.
Risk Assessment
Risk score 59/100 (Moderate). The biggest risk is that box office undershoots AMC's ~$10.4B domestic free-cash-flow breakeven level, leaving a company with $7.7B of debt and a 0.55 current ratio dependent on more equity issuance.
The Bottom Line
AMC rates a BUY at Low conviction. The stock is not a quality story, it is a recovery and balance-sheet extension story, and that distinction matters. The numbers support upside from $2.65 if 2026 box office strength continues and Q2's cash conversion proves repeatable, but the leverage is too high for complacency. A sustained move toward full-year free-cash-flow positivity would raise conviction. A slip back below the $10.4B domestic box-office breakeven path, or renewed heavy dilution, would break the case quickly.
Go deeper in the app
Live charts, options analytics, the full earnings-call breakdown, price alerts, and every other stock — updated in real time.
Get Tickr